Literature DB >> 16882707

Epstein-Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth.

Stephanie Tobollik1, Linda Meyer, Maike Buettner, Sandra Klemmer, Bettina Kempkes, Elisabeth Kremmer, Gerald Niedobitek, Berit Jungnickel.   

Abstract

Somatic hypermutation and class-switch recombination in germinal centers critically depend on activation-induced cytidine deaminase (AID). Deregulation of AID may lead to the aberrant activation or persistence of both genetic processes, thus contributing to the pathogenesis of B-cell lymphomas by mistargeted mutagenesis or recombination. The Epstein-Barr virus (EBV) establishes an asymptomatic latent infection in more than 90% of the human population, but it has also been linked to lymphomagenesis. A cooperative relationship of EBV and the germinal center reaction during the establishment of viral persistence has been postulated, but the contribution of EBV latent genes to the respective genetic events remains to be investigated in detail. In the present study, we show that activation of the EBV growth program has a clear inhibitory effect on AID expression, due to a negative effect of the master transcription factor of this program, EBNA2. This mechanism may counterbalance AID induction by the LMP1 protein, in order to prevent deleterious genetic changes during EBV-induced B-cell growth. EBNA2-mediated AID inhibition also provides a molecular explanation for the previously observed differences in somatic hypermutation activity in EBV-associated lymphoproliferative diseases, thus pointing to a crucial mechanism of EBV-mediated regulation of genomic integrity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16882707     DOI: 10.1182/blood-2006-05-021303

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.

Authors:  Francesco Boccellato; Eleni Anastasiadou; Paola Rosato; Bettina Kempkes; Luigi Frati; Alberto Faggioni; Pankaj Trivedi
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

2.  Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.

Authors:  Wei Zhang; R Stephanie Huang; M Eileen Dolan
Journal:  Trends Cancer Res       Date:  2008

Review 3.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

Review 4.  HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.

Authors:  Marta Epeldegui; Elena Vendrame; Otoniel Martínez-Maza
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

5.  AID expression in peripheral blood of children living in a malaria holoendemic region is associated with changes in B cell subsets and Epstein-Barr virus.

Authors:  Joel R Wilmore; Amolo S Asito; Chungwen Wei; Erwan Piriou; P Odada Sumba; Iñaki Sanz; Rosemary Rochford
Journal:  Int J Cancer       Date:  2014-08-19       Impact factor: 7.396

6.  Regulation of AID expression in the immune response.

Authors:  Elizabeth E Crouch; Zhiyu Li; Makiko Takizawa; Stefan Fichtner-Feigl; Polyxeni Gourzi; Carolina Montaño; Lionel Feigenbaum; Patrick Wilson; Siegfried Janz; F Nina Papavasiliou; Rafael Casellas
Journal:  J Exp Med       Date:  2007-04-23       Impact factor: 14.307

7.  Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.

Authors:  Keigo Machida; Yasuteru Kondo; Jeffrey Y Huang; Yung-Chia Chen; Kevin T-H Cheng; Zhenyong Keck; Steven Foung; Jean Dubuisson; Vicky M-H Sung; Michael M C Lai
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

8.  Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.

Authors:  Hans Lassmann; Gerald Niedobitek; Francesca Aloisi; Jaap M Middeldorp
Journal:  Brain       Date:  2011-08-16       Impact factor: 13.501

9.  The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.

Authors:  Wei Zhang; Mark J Ratain; M Eileen Dolan
Journal:  Bioinform Biol Insights       Date:  2008-02-01

10.  On the challenges of the HapMap resource.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Bioinformation       Date:  2008-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.